Bicycle Therapeutics plc American Depositary Shares
BCYC
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
Last trade$3.17
Day change-$0.01 (-0.31%)
Day range$3.12 – $3.28
Volume308,023
Market cap$223M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$222.9M
Price / earnings
—
Price / book
0.44×
Price / sales
2.67×
EV / sales
-2.96×
EV / EBITDA
1.61×
Profitability
Earnings per share
-$2.02
Return on assets
-25%
Return on equity
-28.06%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
12.09×
Quick ratio
12.09×
Cash ratio
10.57×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$177.04M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BCYC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$34.06M
$629K
$887K
$47.96M
$11.73M
$2.92M
$9.98M
$3.71M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$34.06M
$629K
$887K
$47.96M
$11.73M
$2.92M
$9.98M
$3.71M
Selling, general and administrative
$14.11M
$14.03M
$17.47M
$20.89M
$18.86M
$18.49M
$21.12M
$21.59M
Research and development
$33.42M
$41.16M
$48.9M
$51.77M
$58.43M
$71.03M
$59.06M
$49.78M
Total operating expenses
$47.53M
$55.19M
$66.37M
$72.66M
$77.29M
$89.52M
$80.18M
$71.37M
Operating income
-$13.48M
-$54.56M
-$65.48M
-$24.71M
-$65.55M
-$86.6M
-$70.2M
-$67.66M
Interest expense
-$45K
-$44K
-$48K
-$57K
-$44K
-$54K
-$51K
-$52K
Income before taxes
-$9.31M
-$50.24M
-$60.65M
-$18.89M
-$58.9M
-$79.18M
-$61.84M
-$52.94M
Income taxes
$1.17M
$90K
$172K
$1.27M
$205K
-$231K
-$1.09M
-$1.08M
Net income
-$10.48M
-$50.33M
-$60.83M
-$20.15M
-$59.1M
-$78.95M
-$60.75M
-$51.85M
Net income attributable to common shareholders
-$10.48M
-$50.33M
-$60.83M
-$20.15M
-$59.1M
-$78.95M
-$60.75M
-$51.85M
EBITDA
-$12.4M
-$53.49M
-$64.35M
-$23.37M
-$63.8M
-$84.91M
-$68.57M
-$65.96M
Basic earnings per share
-$0.15
-$0.72
-$0.87
-$0.29
-$0.85
-$1.14
-$0.88
-$0.75
Diluted earnings per share
-$0.15
-$0.72
-$0.87
-$0.29
-$0.85
-$1.14
-$0.88
-$0.75
Recent news
Company coverage with links to the original publishers.
The global Peptide Drug Conjugate (PDC) market is projected to reach $1.5 billion by 2031, growing at over 14% CAGR from 2021-2025. PDCs offer targeted drug delivery solutions for oncology and other diseases with reduced systemic toxicity. The market features over 50 clinical candidates and 18 proprietary technologies, with major players including Novartis, Oncopeptides, Bicycle Therapeutics, Cybrexa Therapeutics, and PepGen driving innovation through strategic partnerships and technological advancements in peptide design and linker technologies.
Bicycle Toxin Conjugates (BTCs) are emerging as a novel targeted oncology technology, offering innovative peptide-based drug delivery with potential applications in cancer treatment and beyond, with early clinical trials showing promising results.
Maxion Therapeutics appointed Dr. Santiago Arroyo as a Non-Executive Director, bringing extensive clinical development expertise from roles at multiple pharmaceutical and biotech companies.
The advanced urothelial carcinoma market is witnessing significant growth, driven by an aging population and the rising prevalence of metastatic cases. Advances in immunotherapy and targeted treatments are transforming the treatment landscape, with over 20 key companies developing new therapies.